These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 2461655

  • 1. Plasma abnormal prothrombin levels in patients with small hepatocellular carcinoma.
    Tanabe Y, Ohnishi K, Nomura F, Iida S.
    Am J Gastroenterol; 1988 Dec; 83(12):1386-9. PubMed ID: 2461655
    [Abstract] [Full Text] [Related]

  • 2. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R, Wang B, Ding H, Shen H, Li Y, Chen X.
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [Abstract] [Full Text] [Related]

  • 3. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
    Fujiyama S, Morishita T, Shibata J, Sato T.
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
    [Abstract] [Full Text] [Related]

  • 4. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
    Tanaka Y, Kashiwagi T, Tsutsumi H, Nagasawa M, Toyama T, Ozaki S, Naito M, Ishibashi K, Azuma M.
    Hepatogastroenterology; 1999 Apr; 46(28):2464-8. PubMed ID: 10522021
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
    Fujiyama S, Morishita T, Sagara K, Sato T, Motohara K, Matsuda I.
    Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS, Park JW, Jang JS, Kim HJ, Shin WG, Kim KH, Lee JH, Kim HY, Jang MK.
    J Clin Gastroenterol; 2009 Oct; 43(5):482-8. PubMed ID: 19197197
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
    Shimizu A, Shiraki K, Ito T, Sugimoto K, Sakai T, Ohmori S, Murata K, Takase K, Tameda Y, Nakano T.
    Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma.
    Nomura F, Ishijima M, Kuwa K, Tanaka N, Nakai T, Ohnishi K.
    Am J Gastroenterol; 1999 Mar; 94(3):650-4. PubMed ID: 10086646
    [Abstract] [Full Text] [Related]

  • 17. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods.
    Nomura F, Ishijima M, Horikoshi A, Nakai T, Ohnishi K.
    Am J Gastroenterol; 1996 Jul; 91(7):1380-3. PubMed ID: 8677999
    [Abstract] [Full Text] [Related]

  • 18. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.
    Lamerz R, Runge M, Stieber P, Meissner E.
    Anticancer Res; 1999 Jul; 19(4A):2489-93. PubMed ID: 10470180
    [Abstract] [Full Text] [Related]

  • 19. Acarboxy prothrombin (PIVKA II) as a tumour marker for hepatocellular carcinoma and other liver diseases.
    Mohamedein A, Yousif-Kadaru AG, Ahmed SA, Saida H, Zaki ZA, Eldin, Fedail SS.
    East Afr Med J; 1995 Sep; 72(9):584-7. PubMed ID: 7498046
    [Abstract] [Full Text] [Related]

  • 20. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
    Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann TA, Afdhal NH.
    Clin Cancer Res; 2008 Jan 15; 14(2):470-7. PubMed ID: 18223221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.